Trial Profile
A clinical study for TAE in combination with anlotinib, oxaliplatin and raltitrexed in the sequential treatment of middle or advanced primary liver cancer (PLC)
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 03 Oct 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Oxaliplatin; Raltitrexed
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Oct 2019 New trial record